Recent blog posts
Exploring the Latest Potential "First-in-Class" Therapy Deal by Karuna Therapeutics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest Potential "First-in-Class" Therapy Deal by Karuna Therapeutics: A Guide to Rapidly Accessing Transaction Insights
25 January 2024
Bristol Myers Squibb (BMS) has agreed to acquire Karuna Therapeutics for around $14 billion, obtaining their novel schizophrenia treatment, KarXT.
Read →
Exploring the Latest Cardiovascular SiRNA Drugs Deal by Argo Biopharma: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest Cardiovascular SiRNA Drugs Deal by Argo Biopharma: A Guide to Rapidly Accessing Transaction Insights
25 January 2024
Argo Biopharma unveiled exclusive RNAi therapy licensing deals with Novartis Pharma.
Read →
Exploring the Latest IL-15 Inhibitor Deal by Calypso Biotech: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
3 min read
Exploring the Latest IL-15 Inhibitor Deal by Calypso Biotech: A Guide to Rapidly Accessing Transaction Insights
24 January 2024
Calypso Biotech to be acquired by Novartis under a deal with a $250M upfront and potential $175M in milestones, with their lead antibody, CALY-002, targeting IL-15.
Read →
Exploring the Latest ETA Antagonists Deal by SanReno Therapeutics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
3 min read
Exploring the Latest ETA Antagonists Deal by SanReno Therapeutics: A Guide to Rapidly Accessing Transaction Insights
22 January 2024
Novartis Pharma will purchase SanReno Therapeutics, enhancing its kidney treatment range. Following the acquisition, SanReno will join Novartis China, advancing clinical trials of two important IgA nephropathy treatments, atrasentan and BION-1301.
Read →
Exploring the Latest dual-mechanism therapy Deal by WindtreeTherapeutics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
5 min read
Exploring the Latest dual-mechanism therapy Deal by WindtreeTherapeutics: A Guide to Rapidly Accessing Transaction Insights
22 January 2024
On Jan 17, 2024, Windtree Therapeutics announced a licensing deal with Lee's Pharm for its heart failure drug istaroxime in Greater China.
Read →
Exploring the Latest ADC Deal by Ambrx Biopharma: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
3 min read
Exploring the Latest ADC Deal by Ambrx Biopharma: A Guide to Rapidly Accessing Transaction Insights
22 January 2024
On January 8, 2024, Johnson & Johnson acquired Ambrx Biopharma for $2 billion to enhance its Antibody-Drug Conjugate (ADC) portfolio, including promising treatments like ARX517 for metastatic prostate cancer.
Read →
Exploring the Latest TSLP monoclonal antibody Deal by Aiolos Bio: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest TSLP monoclonal antibody Deal by Aiolos Bio: A Guide to Rapidly Accessing Transaction Insights
16 January 2024
GSK Plc agreed to buy Aiolos Bio, Inc. for $1 billion, plus up to $400 million in milestones, gaining access to Aiolos’s leading candidate, AIO-001, a long-acting anti-TSLP monoclonal antibody.
Read →
Exploring the Latest PROTACs Deal by Kymera Therapeutics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest PROTACs Deal by Kymera Therapeutics: A Guide to Rapidly Accessing Transaction Insights
16 January 2024
Kymera Therapeutics began their Phase 2 ADVANTA study for KT-474 in AD on Dec 7, 2023, prompting a $15M milestone payment from Sanofi.
Read →
Exploring the Latest PD-L1/SIRPα Bispecific Antibody Deal by Elpiscience Biopharma: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
5 min read
Exploring the Latest PD-L1/SIRPα Bispecific Antibody Deal by Elpiscience Biopharma: A Guide to Rapidly Accessing Transaction Insights
16 January 2024
Elpiscience Biopharma and Astellas Pharma have teamed up in a deal for the BiME® platform, advancing two drugs, ES019 and a second molecular project.
Read →
Exploring the Latest New Endocrine Therapy for ESR1 Mutation Breast Cancer by Shanghai Henlius Biotech: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest New Endocrine Therapy for ESR1 Mutation Breast Cancer by Shanghai Henlius Biotech: A Guide to Rapidly Accessing Transaction Insights
15 January 2024
Henlius Biotech and Sermonix Pharmaceuticals have formed a strategic alliance for the exclusive development, production, and commercialization of the investigational drug lasofoxifene in China.
Read →
Exploring the Latest MSLN ADC Deal by Harbour Biomed Therapeutics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest MSLN ADC Deal by Harbour Biomed Therapeutics: A Guide to Rapidly Accessing Transaction Insights
15 January 2024
Harbour Biomed and its subsidiary Nona Biosciences have entered an exclusive deal with Pfizer for the global development and commercialization of their anti-mesothelin ADC, HBM9033.
Read →
Exploring the Latest KRAS G12C Inhibitor Deal by Innovent Biologics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest KRAS G12C Inhibitor Deal by Innovent Biologics: A Guide to Rapidly Accessing Transaction Insights
13 January 2024
The CDE recently accepted Innovent Biologics and GenFleet Therapeutics' joint NDA for GF-105, prioritizing its review for advanced NSCLC patients with the KRAS G12C mutation after first-line therapy.
Read →